Joseph Conlon, MD
Internal Medicine · Wilmington, DENPI 1790129724
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations.
Across 209 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$537
- Lilly USA, LLC$500
- GSK$342
- Amgen$319
- Novo Nordisk$308
- Astellas Pharma US Inc$200
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,655100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $537 |
| Lilly USA, LLC | 28 | $500 |
| GSK | 21 | $342 |
| Amgen | 20 | $319 |
| Novo Nordisk | 16 | $308 |
| Astellas Pharma US Inc | 12 | $200 |
| Kowa Pharmaceuticals America, Inc. | 13 | $180 |
| Merck | 10 | $144 |
| Biocryst US Sales Co., LLC | 4 | $131 |
| Abbott | 6 | $108 |
| Sumitomo Pharma America, Inc. | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $91 |
| Paratek Pharmaceuticals, Inc. | 4 | $82 |
| AstraZeneca | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Eisai Inc. | 3 | $48 |
| Boehringer Ingelheim | 4 | $48 |
| Amarin Pharma, Inc. | 2 | $45 |
| Pfizer | 3 | $41 |
| CSL Behring | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $21 |
| Heartflow, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Digestive Care, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,655 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $64,489 |
| MyrbetriqMirabegron | 53 | $57,634 |
| XareltoRivaroxaban | 21 | $32,258 |
| OzempicSemaglutide | 29 | $29,933 |
| JanuviaSitagliptin Phosphate | 12 | $17,971 |
| MounjaroTirzepatide | 14 | $16,424 |
| TrulicityDulaglutide | 17 | $15,584 |
| JardianceEmpagliflozin | 11 | $15,547 |
| Repatha SureclickEvolocumab | 19 | $15,145 |
| Rosuvastatin Calcium | 260 | $7,834 |
| SynthroidLevothyroxine Sodium | 40 | $3,824 |
| Esomeprazole Magnesium | 38 | $2,979 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,886 |
| Amlodipine Besylate | 176 | $2,865 |
| Fentanyl | 12 | $2,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $64,48938 claims |
| Astellas Pharma US IncMyrbetriq | $200 | $57,63453 claims |
| Lilly USA, LLCMounjaro, Trulicity | $500 | $32,00831 claims |
| Novo NordiskOzempic | $308 | $29,93329 claims |
| MerckJanuvia | $144 | $17,97112 claims |
| Boehringer IngelheimJardiance | $48 | $15,54711 claims |
| AbbVieSynthroid | $537 | $3,82440 claims |
| GSKShingrix | $342 | $2,88613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Wilmington
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Robert KopeckiWilmington$15K
- Franklin AmpaduWilmington$15K
- Andrew MyersWilmington$15K
- Armand DesanctisWilmington$11K
- Carol Alvarado-BarrantesWilmington$10K
- Stuart FelzerWilmington$6K
- Terry HortonWilmington$5K
- Jerry GluckmanWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.